The role of single instillation chemotherapy in patients who receive subsequent bacillus Calmette-Guérin: A retrospective single centre study, and systematic review of the literature.
BACKGROUND
This retrospective study was undertaken to evaluate the combined effect of immediate intravesical chemotherapy and subsequent bacillus Calmette-Guérin (BCG) therapy.


METHODS
The study population consisted of 207 intermediate- or high-risk patients with non-muscle invasive bladder cancer who underwent an induction course of BCG between 1993 and 2007. We introduced single immediate instillation of 50 mg epirubicin for all cases in 2004, and thus earlier cases could be considered as historical controls. The primary endpoint was recurrence-free survival (RFS). For cumulative analysis, we systematically reviewed studies indexed in databases. Including ours, the records of 856 patients from a total of 7 studies, including ours, were finally analyzed.


RESULTS
In our cohort, the 5-year RFS in patients who received the combination therapy was 66.2%, compared to 55.2% in the BCG alone group (p = 0.149). Multivariate analysis on tumour recurrence showed that patients with the combination therapy had a hazard ratio (HR) of 0.74 (p = 0.189). A subsequent literature review revealed that RFS rates in the combination groups were higher than those in the corresponding BCG alone groups in 4/7 studies (p = 0.02-0.15), and lower in 1 study (p = 0.51). We identified 5 studies which examined a HR for combination therapy, and performed a cumulative analysis. Adding a single chemo-instillation prior to BCG resulted in a significant reduction in tumour recurrence (summary HR 0.69, p = 0.010).


CONCLUSIONS
Our analysis suggested that the combination of single chemo-instillation with subsequent BCG therapy exhibited an additive effect against potential tumour recurrence.
Tokyo Saiseikai Central Hospital, Department of Urology, Minato-ku, Tokyo, Japan.
Kazuhiro
K
Matsumoto
Tokyo Saiseikai Central Hospital, Department of Urology, Minato-ku, Tokyo, Japan.
Tatsuo
T
Gondo
Tokyo Saiseikai Central Hospital, Department of Urology, Minato-ku, Tokyo, Japan.
Nozomi
N
Hayakawa
Tokyo Saiseikai Central Hospital, Department of Urology, Minato-ku, Tokyo, Japan.
Takahiro
T
Maeda
Tokyo Saiseikai Central Hospital, Department of Urology, Minato-ku, Tokyo, Japan.
Akiharu
A
Ninomiya
Tokyo Saiseikai Central Hospital, Department of Urology, Minato-ku, Tokyo, Japan.
So
S
Nakamura